InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (2 ops.)
Insider track record
ExecutiveDisclosed buys
6
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Lu Hongbo, Director. Officer active across 3 companies, notably Arrowhead Pharmaceuticals, INC.. Aggregated, 9 reports have been published. Split: 6 buys · 2 sells. Total volume traded: €13.7m. History available since 12 August 2022. The latest transaction was disclosed on 12 May 2026 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations9 total
2,970 shares@ US$76.880.0017% mcap50.0% of flowCommon StockSEC:0001767584-26-000002
2,970 shares@ US$76.880.0018% mcap50.0% of flowCommon StockSEC:0001767584-26-000002:0
16,733 shares@ US$22.9946.9% of flowCommon StockSEC:0001628280-24-052268:0
190,476 shares@ US$10.5014.6% of flowCommon StockSEC:0000919574-24-005529:0
Ideal exit: 9 Jun 2025 (T+270)
58,823 shares@ US$17.00100.0% of flowCommon StockSEC:0000919574-24-005530:0
Ideal exit: 10 Jun 2025 (T+270)
1,000 shares@ US$27.493.2% of flowCommon StockSEC:0001628280-24-012327:0
Ideal exit: 13 Dec 2024 (T+270)
758,620 shares@ US$7.2541.8% of flowCommon StockSEC:0001562180-22-008428:0
Ideal exit: 19 Sept 2023 (T+270)
600,000 shares@ US$3.6017.4% of flowCommon StockSEC:0001562180-22-006567:0
Ideal exit: 4 Jun 2023 (T+270)
1,123,021 shares@ US$2.9826.2% of flowCommon StockSEC:0001562180-22-006125:0
Ideal exit: 9 May 2023 (T+270)
9 of 9 declarations
